Privi Speciality Chemicals Limited has informed the Exchange about Transcript
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Privi Speciality Chemicals reported strong Q1 FY'26 results with consolidated revenue of ~Rs. 568 crores (up ~22% YoY), EBITDA of Rs. 141 crores (up ~45% YoY) at a margin of 24.8%, and profit after tax of ~Rs. 61 crores versus Rs. 32 crores a year ago. Management reiterated its 5K-1K vision — Rs. 5,000 crore revenue and Rs. 1,000 crore EBITDA in the next 3-5 years, with sustained EBITDA margins of 20% or more. The company announced a proposed amalgamation of Privi Fine Sciences and Privi Biotechnologies into itself, disclosed an overall capex plan of ~Rs. 1,100 crores (phase 1 of ~Rs. 280-300 crores underway), and highlighted new products like cyclopentanol and anethole. The board also earned a platinum EcoVadis rating (top 1% globally for ESG) and is considering a stock split to improve liquidity after a senior promoter (~3.5-4% stake) trimmed holdings. Exports contribute ~70% of revenue, with US exposure limited to ~7%, limiting tariff risk.
Positive for shareholders: strong double-digit revenue and EBITDA growth, reaffirmed long-term targets, and operational improvements from continuous plant conversion support margin durability. Stock split consideration may improve liquidity, while the amalgamation and capex roadmap lay out a clear growth path through FY29.